What Is PGT-A

PGT-A (Preimplantation Genetic Testing for Aneuploidy) is performed before embryo transfer. A small number of cells from the outer trophectoderm layer of a blastocyst are sampled to check whether the chromosome count is normal. It screens out embryos with an extra or missing chromosome, thereby reducing the miscarriage rate and improving the single-transfer implantation rate — especially beneficial for advanced maternal age and repeated failure.

In simple terms, PGT-A helps your doctor pick the embryo most likely to become a healthy baby, so that each transfer has the best possible chance. It is one tool within a broader strategy, not a substitute for good ovarian stimulation and embryo culture.

Differences Within the PGT Family

  • PGT-A : Screens for numerical chromosomal abnormalities (such as trisomy 21 and trisomy 18), suitable for most older patients and those with recurrent miscarriage.
  • PGT-M : Targets single-gene disorders (such as thalassemia and spinal muscular atrophy), requiring family verification.
  • PGT-SR : Targets structural chromosomal rearrangements (such as balanced translocations and inversions), reducing the risk of recurrent miscarriage.

Who Should Consider PGT-A

  • Female age ≥ 35 (aneuploidy risk rises with age).
  • Recurrent miscarriage (≥ 2 times) or repeated implantation failure.
  • Severe male-factor infertility or a history of chromosomally abnormal pregnancy.

Your doctor will weigh whether it is necessary based on your situation — it is not required for everyone.

The Testing Process

Blastocyst biopsy → Next-Generation Sequencing (NGS) → select euploid (normal) embryos for frozen storage, then transfer a single embryo at the optimal time, maximizing the efficiency and safety of each transfer.

Because the biopsy is performed at the blastocyst stage and the cells sampled come from the trophectoderm (which becomes the placenta, not the fetus), the procedure does not harm the inner cell mass that forms the baby. The embryo is frozen while the laboratory analyzes the sample, and the results typically guide a transfer scheduled for a later, natural cycle.

About “Mosaic” Embryos

Some embryos test as mosaic (a mix of normal and abnormal cells). Whether to transfer one should be assessed jointly by a genetic counselor and your doctor, considering the mosaic ratio, the chromosomes involved, and the patient’s wishes. They are not discarded automatically — many low-level mosaic embryos can still result in a healthy pregnancy.

Clinical Value and Cautions

PGT-A improves the efficiency of each transfer and reduces futile transfers, but it cannot guarantee a 100% pregnancy , nor does it screen for all birth defects (such as structural malformations or polygenic diseases). It adds to the total cycle cost, so the benefit must be weighed with your doctor before deciding.

Cost and Waiting Time

PGT-A requires biopsy at the blastocyst stage and outsourced sequencing, adding several weeks of waiting and some cost. However, it reduces the physical, emotional, and financial toll of repeated failure and miscarriage, and for older patients and those with repeated failure it often “saves more than it costs.” Specific pricing is detailed by the center at your initial consultation.

The State of PGT Technology in China

China enforces strict accreditation for PGT — only approved fertility centers may perform it. In recent years, the widespread adoption of NGS (Next-Generation Sequencing) has greatly improved both precision and accessibility, approaching international standards. Patients can now receive standardized, compliant third-generation IVF services locally.

Want to assess whether PGT-A is right for you? The International Department of Luohu Hospital in Shenzhen is accredited for third-generation IVF. A complete IVF cycle costs about $4,500–6,000 , which is 60–70% lower than in the United States . Book a consultation: /consultation/, or reach us on WhatsApp: https://wa.me/8618886468446